Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
View Patent ↗A process for the preparation of a quaternary derivative of the morphinan alkaloid, the process comprising contacting a tertiary N-substituted morphinan alkaloid with an alkyl halide in an anhydrous solvent system, wherein the solvent system comprises an aprotic dipolar solvent with the aprotic dipolar solvent constituting at least 25 wt. % of the solvent system.
1. A process for the preparation of a quaternary derivative of a tertiary N-substituted morphinan alkaloid, the process comprising contacting a tertiary N-substituted morphinan alkaloid substrate with an alkylating agent in an anhydrous solvent system, wherein the solvent system comprises an aprotic dipolar solvent selected from the group consisting of dimethylacetamide, dimethylformamide, 1-methyl-2-pyrrolidinone, hexamethylphosphoramide, and mixtures thereof with the aprotic dipolar solvent constituting at least 25 wt % of the solvent system, the contacting is carried out within a temperature range of about 55° C. to about 85° C., the tertiary N-substituted morphinan alkaloid substrate and the quaternary derivative correspond to Formulae 1 and Formula 1A, respectively:
A is —C(O)—, —C(S)—, —C(═CH 2 )—, —CH(A 1 )—, or —C(A 1 )═,
A 1 is hydroxy, alkoxy, or acyloxy,
each R is independently hydrocarbyl,
R 1 is hydrocarbyl or substituted hydrocarbyl,
R 2 is hydrocarbyl or substituted hydrocarbyl,
X θ is an anion,
Y, if present, is hydrogen, hydroxy, alkoxy, acyloxy, —OTHP, —OSiR 3 , —OBn, —OBs, —OTs, or OMs,
Z is hydroxy, alkoxy, acyloxy, —OTHP, —OSiR 3 , —OBn, —OBs, —OTs, or —OMs, and
the dashed lines between the carbon atoms at positions 6 and 7, 7 and 8, and 8 and 14, respectively, represent (i) carbon-carbon single bonds, (ii) carbon-carbon single bonds between positions 6 and 7 and between positions 8 and 14, and a double bond between positions 7 and 8, or (iii) conjugated carbon-carbon double bonds between positions 6 and 7 and positions 8 and 14, with the proviso that Y is not present if there is a double bond between the carbons at positions 8 and 14.
2. The process of claim 1 wherein the tertiary N-substituted morphinan alkaloid substrate and the quaternary derivative correspond to Formula 2 and 2A, respectively:
A is —C(O)—, —C(S)—, —C(═CH 2 )—, or —CH(A 1 )—,
A 1 is hydroxy, alkoxy, or acyloxy,
R 1 is hydrocarbyl or substituted hydrocarbyl,
R 2 is hydrocarbyl or substituted hydrocarbyl,
X θ is an anion,
Y is hydrogen, hydroxy, alkoxy, or acyloxy, and
Z is hydroxy, alkoxy, or acyloxy.
3. The process of claim 2 wherein the tertiary N-substituted morphinan alkaloid substrate is naltrexone ((5α)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one), oxymorphone ((5α)-4,5-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one), oxycodone ((5α)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one), hydromorphone ((5α)-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-one), naloxone ((5α)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one), nalmefene ((5α)-17-(cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol) or nalbuphine ((5α)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol).
4. The process of claim 1 wherein the alkylating agent is methyl bromide.
5. The process according to claim 1 wherein said process is carried out at a pressure of less than 1.25 atmospheres.
6. The process according to claim 1 wherein the aprotic dipolar solvent constitutes at least 75 wt. % of the solvent system.
7. The process according to claim 1 wherein said aprotic dipolar solvent is 1-methyl-2-pyrrolidinone.
8. The process according to claim 1 wherein Y and Z are independently —OCH 3 , —OAc, —OTHP, —OSiR 3 , —OBn, —OBz, —OBs, —OTs, or —OMs wherein each R is independently hydrocarbyl.
9. The process according to claim 1 wherein said anhydrous solvent system contains less than 0.2 wt. % water and is maintained in a moisture-free atmosphere in a reaction vessel.
10. The process according to claim 1 wherein said anhydrous solvent system contains less than 0.1 wt. % water.
11. The process according to claim 1 wherein said anhydrous solvent system contains less than 0.05 wt. % water.
12. The process according to claim 11 wherein said alkylating agent is a methylating agent.
13. The process according to claim 11 wherein said alkylating agent and said substrate are present in a mole ratio of between 1:1 and 1.5:1, respectively.
14. The process according to claim 1 wherein said anhydrous solvent system and said substrate are present in a volume-to-weight ratio of 1.5:1-1.75:1.
15. The process of claim 1 wherein the tertiary N-substituted morphinan alkaloid substrate and the quaternary derivative correspond to Formulae 3 and 3A, respectively:
A is —C(O)—, —C(S)—, —C(═CH 2 )—, or —CH(A 1 )—,
A 1 is hydroxy, alkoxy, or acyloxy,
R 1 is hydrocarbyl or substituted hydrocarbyl,
R 2 is hydrocarbyl or substituted hydrocarbyl, and
X θ is an anion,
Y is hydrogen, hydroxy, alkoxy, or acyloxy, and
Z is hydroxy, alkoxy, or acyloxy.
16. The process of claim 15 wherein the tertiary N-substituted morphinan alkaloid substrate is morphine ((5α,6α)-7,8-didehydro-4,5-epoxi-17-methylmorphinan-3,6-diol), codeine ((5α,6α)-7,8-didehydro-4,5-epoxi-3-methoxy-17-methylmorphinan-6-ol), codeinone ((5α)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-one) or 14-hydroxy-codeinone ((5α)-7,8-didehydro-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one).
17. The process of claim 1 wherein the tertiary N-substituted morphinan alkaloid substrate and the quaternary derivative correspond to Formulae 4 and 4A, respectively:
A 1 is hydroxy, alkoxy, or acyloxy,
R 1 is hydrocarbyl or substituted hydrocarbyl,
R 2 is hydrocarbyl or substituted hydrocarbyl,
X θ is an anion, and
Z is hydroxy, alkoxy, or acyloxy.
18. A process for the preparation of a quaternary derivative of a tertiary N-substituted morphinan alkaloid, the process comprising contacting a tertiary N-substituted morphinan alkaloid substrate with an alkylating agent in an anhydrous solvent system, wherein the solvent system comprises 1-methyl-2-pyrrolidinone with the 1-methyl-2-pyrrolidinone constituting at least 25 wt % of the solvent system, the tertiary N-substituted morphinan alkaloid substrate and the quaternary derivative correspond to Formulae 1 and 1A, respectively:
A is —C(O)—, —C(S)—, —C(═CH 2 )—, —CH(A 1 )—, or —C(A 1 )═,
A 1 is hydroxy, alkoxy, or acyloxy,
each R is independently hydrocarbyl,
R 1 is hydrocarbyl or substituted hydrocarbyl,
R 2 is hydrocarbyl or substituted hydrocarbyl,
X θ is an anion,
Y, if present, is hydrogen, hydroxy, alkoxy, acyloxy, —OTHP, —OSiR 3 , —OBn, —OBs, —OTs, or —OMs,
Z is hydroxy, alkoxy, acyloxy, —OTHP, —OSiR 3 , —OBn, —OBs, —OTs, or —OMs, and the dashed lines between the carbon atoms at positions 6 and 7, 7 and 8, and 8 and 14, respectively, represent (i) carbon-carbon single bonds, (ii) carbon-carbon single bonds between positions 6 and 7 and between positions 8 and 14, and a double bond between positions 7 and 8, or (iii) conjugated carbon-carbon double bonds between positions 6 and 7 and positions 8 and 14, with the proviso that Y is not present if there is a double bond between the carbons at positions 8 and 14.
19. The process of claim 18 wherein the tertiary N-substituted morphinan alkaloid substrate and the quaternary derivative correspond to Formulae 2 and 2A, respectively:
A is —C(O)—, —C(S)—, —C(═CH 2 )—, or —CH(A 1 )—,
A 1 is hydroxy, alkoxy, or acyloxy,
R 1 is hydrocarbyl or substituted hydrocarbyl,
R 2 is hydrocarbyl or substituted hydrocarbyl,
X θ is an anion,
Y is hydrogen, hydroxy, alkoxy, or acyloxy, and
Z is hydroxy, alkoxy, or acyloxy.
20. The process of claim 19 wherein the tertiary N-substituted morphinan alkaloid substrate is naltrexone ((5α)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one), oxymorphone ((5α)-4,5-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one), oxycodone ((5α)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one), hydromorphone ((5α)-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-one), naloxone ((5α)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one), nalmefene ((5α)-17-(cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol) or nalbuphine ((5α)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol).
21. The process of claim 18 wherein the alkylating agent is methyl bromide.
22. The process according to claim 18 wherein said process is carried out at a pressure of less than 1.25 atmospheres.
23. The process according to claim 18 wherein the 1-methyl-2-pyrrolidinone constitutes at least 75 wt. % of the solvent system.
24. The process according to claim 18 wherein Y and Z are independently —OCH3, —OAc, —OTHP, —OSiR 3 , —OBn, —OBz, —OBs, —OTs, or —OMs wherein each R is independently hydrocarbyl.
25. The process according to claim 18 wherein said anhydrous solvent system contains less than 0.2 wt. % water and is maintained in a moisture-free atmosphere in a reaction vessel.
26. The process according to claim 18 wherein said anhydrous solvent system contains less than 0.1 wt. % water.
27. The process according to claim 18 wherein said anhydrous solvent system contains less than 0.05 wt. % water.
28. The process according to claim 27 wherein said alkylating agent is a methylating agent.
29. The process according to claim 27 wherein said alkylating agent and said substrate are present in a mole ratio of between 1:1 and 1.5:1, respectively.
30. The process according to claim 18 wherein said 1-methyl-2-pyrrolidinone and said substrate are present in a volume-to-weight ratio of 1.5:1-1.75:1.
31. The process according to claim 18 wherein said contacting is carried out within a temperature range of about 55° C. to about 85° C.
32. The process of claim 18 wherein the tertiary N-substituted morphinan alkaloid substrate and the quaternary derivative correspond to Formulae 3 and 3A, respectively:
A is —C(O)—, —C(S)—, —C(═CH 2 )—, or —CH(A 1 )—,
A 1 is hydroxy, alkoxy, or acyloxy,
R 1 is hydrocarbyl or substituted hydrocarbyl,
R 2 is hydrocarbyl or substituted hydrocarbyl,
X θ is an anion,
Y is hydrogen, hydroxy, alkoxy, or acyloxy, and
Z is hydroxy, alkoxy, or acyloxy.
33. The process of claim 32 wherein the tertiary N-substituted morphinan alkaloid substrate is morphine ((5α,6α)-7,8-didehydro-4,5-epoxi-17-methylmorphinan-3,6-diol), codeine ((5α,6α)-7,8-didehydro-4,5-epoxi-3-methoxy-17-methylmorphinan-6-ol), codeinone ((5α)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-one) or 14-hydroxy-codeinone ((5α)-7,8-didehydro-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one).
34. The process of claim 18 wherein the tertiary N-substituted morphinan alkaloid substrate and the quaternary derivative correspond to Formulae 4 and 4A, respectively:
A 1 is hydroxy, alkoxy, or acyloxy,
R 1 is hydrocarbyl or substituted hydrocarbyl,
R 2 is hydrocarbyl or substituted hydrocarbyl,
X θ is an anion, and
Z is hydroxy, alkoxy, or acyloxy.
35. A process for the preparation of a quaternary derivative of a tertiary N-substituted morphinan alkaloid, the process comprising contacting a tertiary N-substituted morphinan alkaloid substrate with methyl bromide in an anhydrous solvent system, wherein the solvent system comprises an aprotic dipolar solvent selected from the group consisting of dimethylacetamide, dimethylformamide, 1-methyl-2-pyrrolidinone, hexamethylphosphoramide, and mixtures thereof with the aprotic dipolar solvent constituting at least 25 wt % of the solvent system, the tertiary N-substituted morphinan alkaloid substrate and the quaternary derivative have the structures of Formulae 1 and 1A, respectively:
A is —C(O)—, —C(S)—, —C(═CH 2 )—, —CH(A 1 )—, or —C(A 1 )═,
A 1 is hydroxy, alkoxy, or acyloxy,
each R is independently hydrocarbyl,
R 1 is hydrocarbyl or substituted hydrocarbyl,
R 2 is hydrocarbyl or substituted hydrocarbyl,
X θ is an anion,
Y, if present, is hydrogen, hydroxy, alkoxy, acyloxy, —OTHP, —OSiR 3 , —OBn, —OBs, —OTs, or —OMs,
Z is hydroxy, alkoxy, acyloxy, —OTHP, —OSiR 3 , —OBn, —OBs, —OTs, or —OMs, and the dashed lines between the carbon atoms at positions 6 and 7, 7 and 8, and 8 and 14, respectively, represent (i) carbon-carbon single bonds, (ii) carbon-carbon single bonds between positions 6 and 7 and between positions 8 and 14, and a double bond between positions 7 and 8, or (iii) conjugated carbon-carbon double bonds between positions 6 and 7 and positions 8 and 14, with the proviso that Y is not present if there is a double bond between the carbons at positions 8 and 14.
36. The process of claim 35 wherein the tertiary N-substituted morphinan alkaloid substrate and the quaternary derivative correspond to Formulae 2 and 2A, respectively:
A is —C(O)—, —C(S)—, —C(═CH 2 )—, or —CH(A 1 )—,
A 1 is hydroxy, alkoxy, or acyloxy,
R 1 is hydrocarbyl or substituted hydrocarbyl,
R 2 is hydrocarbyl or substituted hydrocarbyl,
X θ is an anion,
Y is hydrogen, hydroxy, alkoxy, or acyloxy, and
Z is hydroxy, alkoxy, or acyloxy.
37. The process of claim 36 wherein the tertiary N-substituted morphinan alkaloid substrate is naltrexone ((5α)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one), oxymorphone ((5α)-4,5-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one), oxycodone ((5α)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one), hydromorphone ((5α)-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-one), naloxone ((5α)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one), nalmefene ((5α)-17-(cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol) or nalbuphine ((5α)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol).
38. The process according to claim 35 wherein said process is carried out at a pressure of less than 1.25 atmospheres.
39. The process according to claim 35 wherein the aprotic dipolar solvent constitutes at least 75 wt. % of the solvent system.
40. The process according to claim 35 wherein said aprotic dipolar solvent is 1-methyl-2-pyrrolidinone.
41. The process according to claim 35 wherein Y and Z are independently —OCH 3 , —OAc, —OTHP, —OSiR 3 , —OBn, —OBz, —OBs, —OTs, or —OMs wherein each R is independently hydrocarbyl.
42. The process according to claim 35 wherein said anhydrous solvent system contains less than 0.2 wt. % water and is maintained in a moisture-free atmosphere in a reaction vessel.
43. The process according to claim 35 wherein said anhydrous solvent system contains less than 0.1 wt. % water.
44. The process according to claim 35 wherein said anhydrous solvent system contains less than 0.05 wt. % water.
45. The process according to claim 44 wherein said methyl bromide and said substrate are present in a mole ratio of between 1:1 and 1.5:1, respectively.
46. The process according to claim 35 wherein said anhydrous solvent system and said substrate are present in a volume-to-weight ratio of 1.5:1-1.75:1.
47. The process according to claim 35 wherein said contacting is carried out within a temperature range of about 55° C. to about 85° C.
48. The process of claim 35 wherein the tertiary N-substituted morphinan alkaloid substrate and the quaternary derivative correspond to Formulae 3 and 3A, respectively:
A is —C(O)—, —C(S)—, —C(═CH 2 )—, or —CH(A 1 )—,
A 1 is hydroxy, alkoxy, or acyloxy,
R 1 is hydrocarbyl or substituted hydrocarbyl,
R 2 is hydrocarbyl or substituted hydrocarbyl,
X θ is an anion,
Y is hydrogen, hydroxy, alkoxy, or acyloxy, and
Z is hydroxy, alkoxy, or acyloxy.
49. The process of claim 48 wherein the tertiary N-substituted morphinan alkaloid substrate is morphine ((5α,6α)-7,8-didehydro-4,5-epoxi-17-methylmorphinan-3,6-diol), codeine ((5α,6α)-7,8-didehydro-4,5-epoxi-3-methoxy-17-methylmorphinan-6-ol), codeinone ((5α)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-one) or 14-hydroxy-codeinone ((5α)-7,8-didehydro-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one).
50. The process of claim 35 wherein the tertiary N-substituted morphinan alkaloid substrate and the quaternary derivative correspond to Formulae 4 and 4A, respectively:
A 1 is hydroxy, alkoxy, or acyloxy,
R 1 is hydrocarbyl or substituted hydrocarbyl,
R 2 is hydrocarbyl or substituted hydrocarbyl,
X θ is an anion, and
Z is hydroxy, alkoxy, or acyloxy.